miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint

Nature Communications

Volumn 7, Issue , 2016, Pages

  Xu, Shaohua ^a   Tao, Zhen ^b   Hai, Bo ^c   Liang, Huagen ^c   Shi, Ying ^c   Wang, Tao ^c   Song, Wen ^c   Chen, Yong ^c   OuYang, Jun ^d   Chen, Jinhong ^a   Kong, Fanfei ^a   Dong, Yishan ^d   Jiang, Shi Wen ^e   Li, Weiyong ^c   Wang, Ping ^b   Yuan, Zhiyong ^b   Wan, Xiaoping ^a   Wang, Chenguang ^f   Li, Wencheng ^c   Zhang, Xiaoping ^c   Chen, Ke ^c   more..

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

^e MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MICRORNA; MICRORNA 424; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; MIRN322 MICRORNA, MOUSE; MIRN424 MICRORNA, HUMAN;

CANCER; CELLS AND CELL COMPONENTS; CHEMOTHERAPY; DISEASE TREATMENT; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOASSAY; INHIBITION; PHYSIOLOGICAL RESPONSE; TUMOR;

3' UNTRANSLATED REGION; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTOPOIESIS; MOUSE; NONHUMAN; OVARY CANCER; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DRUG RESISTANCE; FEMALE; GENETICS; IMMUNOLOGY; OVARY TUMOR; PATHOPHYSIOLOGY;

ANIMALS; B7-1 ANTIGEN; B7-H1 ANTIGEN; CELL PROLIFERATION; CTLA-4 ANTIGEN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICRORNAS; OVARIAN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84966270957     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11406     Document Type: Article

References (39)

1. Cannistra, S. A. Cancer of the ovary. N. Engl. J. Med. 351, 2519-2529 (2004).
2. Gagnon, A. et al. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin. Cancer Res. 14, 764-771 (2008).
3. Odunsi, K. et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 63, 6076-6083 (2003).
4. Greenlee, R. T., Hill-Harmon, M. B., Murray, T. & Thun, M. Cancer statistics, 2001. CA Cancer J. Clin. 51, 15-36 (2001).
5. Armstrong, D. K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7(Suppl 5): 20-28 (2002).
6. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
7. Abiko, K. et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin. Cancer Res. 19, 1363-1374 (2013).
8. Quezada, S. A., Peggs, K. S., Simpson, T. R. & Allison, J. P. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol. Rev. 241, 104-118 (2011).
9. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
10. Wainwright, D. A. et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin. Cancer Res. 20, 5290-5301 (2014).
11. Xu, C. et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 25, 590-604 (2014).
12. Wang, X. et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell. Signal. 27, 443-452 (2015).
13. Felekkis, K., Touvana, E., Stefanou, C. & Deltas, C. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia 14, 236-240 (2010).
14. Ha, T. Y. The role of MicroRNAs in regulatory T cells and in the immune response. Immune Netw. 11, 11-41 (2011).
15. Chen, L. et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat. Commun. 5, 5241 (2014).
16. Gong, A. Y. et al. MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J. Immunol. 182, 1325-1333 (2009).
17. Gong, A. Y. et al. Cryptosporidium parvum induces B7-H1 expression in cholangiocytes by down-regulating microRNA-513. J. Infect. Dis. 201, 160-169 (2010).
18. Hoeppli, R. E., Wu, D., Cook, L. & Levings, M. K. The environment of regulatory T cell biology: cytokines, metabolites, and the microbiome. Front. Immunol. 6, 61 (2015).
19. Blank, C., Gajewski, T. F. & Mackensen, A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol. Immunother. 54, 307-314 (2005).
20. Igney, F. H. & Krammer, P. H. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukoc. Biol. 71, 907-920 (2002).
21. Chen, J. et al. Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 217, 385-393 (2012).
22. Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687-695 (2014).
23. Lindau, D., Gielen, P., Kroesen, M., Wesseling, P. & Adema, G. J. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138, 105-115 (2013).
24. Ghanekar, S. A. et al. Gamma interferon expression in CD8( + ) T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65. Clin. Diagn. Lab. Immunol. 8, 628-631 (2001).
25. Baksh, K. & Weber, J. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. Semin. Oncol. 42, 363-377 (2015).
26. Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974-1982 (2015).
27. Momtaz, P. & Postow, M. A. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers. Med. 7, 357-365 (2014).
28. Kelnar, K., Peltier, H. J., Leatherbury, N., Stoudemire, J. & Bader, A. G. Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates. Anal. Chem. 86, 1534-1542 (2014).
29. Nagaraj, A. B., Joseph, P. & DiFeo, A. miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer. Biomarkers Med. 9, 241-257 (2015).
30. Duraiswamy, J., Freeman, G. J. & Coukos, G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 73, 6900-6912 (2013).
31. Alvarez Arias, D. A. et al. Disruption of CD8 + Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity. Cancer Immunol. Res. 2, 207-216 (2014).
32. Abad, C. et al. Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma. J. Leukoc. Biol. 95, 357-367 (2014).
33. Wang, C. J. et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc. Natl Acad. Sci. USA 112, 524-529 (2015).
34. Xu, S. et al. The biphasic expression pattern of miR-200a and E-cadherin in epithelial ovarian cancer and its correlation with clinicopathological features. Curr. Pharm. Des. 20, 1888-1895 (2014).
35. Wang, T. et al. The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer. Oncotarget 5, 3611-3621 (2014).
36. Wang, T. et al. Flightless I homolog represses prostate cancer progression through targeting androgen receptor signaling. Clin. Cancer Res. 22, 1531-1544 (2016).
37. Cai, Q., Yan, L. & Xu, Y. Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells. Oncogene 34, 3315-3324 (2014).
38. Lu, L. et al. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizeswith chemotherapeutic drugs. J. Transl. Med. 12, 36 (2014).
39. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).